Holen Sie sich die Stockscreener-App
32.71
2.44%
0.78
Handel nachbörslich:
32.80
0.09
+0.28%
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
EcoR1 Capital LLC Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Inc (STOK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates - BioSpace
Stoke Therapeutics Inc (STOK) Cash Flow - TradingKey
Stoke Therapeutics Inc (STOK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Stoke Therapeutics Inc (STOK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Stoke Therapeutics Inc (STOK) Institutional Confidence - TradingKey
Troluce Capital Advisors LLC Buys Shares of 652,800 Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Inc (STOK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Stoke Therapeutics Inc (STOK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
STOK|Stoke Therapeutics Inc|Price:29.320|Chg%:+0.020 - TradingKey
Stoke Therapeutics Inc (STOK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Granahan Investment Management LLC Has $10.93 Million Stock Holdings in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. Revenue Breakdown – NASDAQ:STOK - TradingView
Siren L.L.C. Sells 252,000 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Inc (STOK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
(STOK) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Stoke Therapeutics (STOK) Edges Higher, Testing Resistance at $30.41ADD Alert - dars.gov.et
Stoke Therapeutics Inc (STOK) - MSN
Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch (NASDAQ:STOK) - Seeking Alpha
Stoke Therapeutics Chief Scientific Officer Thomas McCauley files initial beneficial ownership statement - Bitget
Form 4 Stoke Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Form 4 Stoke Therapeutics Inc For: 17 July - Investing.com India
Stoke Therapeutics (STOK) director gifts 303,190 options to trust - Stock Titan
Stoke Therapeutics (STOK) awards 225,000 stock options to Chief Scientific Officer - Stock Titan
Stoke Therapeutics (STOK) CSO Thomas McCauley files initial insider report - Stock Titan
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 16, 2026 - BioSpace
Stoke Therapeutics grants CSO McCauley options for 225,000 shares at $29.91 each - Bitget
Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at The Goldman Sachs Group - MarketBeat
Stoke Therapeutics (STOK) Declines Slightly as Stock Consolidates Near ResistanceStock Analysis - dars.gov.et
Jefferies Initiates Stoke Therapeutics(STOK.US) With Buy Rating, Announces Target Price $44 - Moomoo
Stoke Therapeutics appoints Thomas McCauley as CSO By Investing.com - Investing.com India
Stoke Tx appoints Thomas McCauley as CSO - The Pharma Letter
Stoke Therapeutics Appoints Thomas McCauley as Chief Scientific Officer - citybiz
Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential - Investing.com UK
Stoke Therapeutics Taps Dr. Thomas McCauley as Chief Scientific Officer - Contract Pharma
Stoke Therapeutics Announces Appointment of Thomas McCauley as Chief Scientific Officer - marketscreener.com
Stoke Therapeutics appoints Thomas McCauley as CSO - Investing.com
Goldman Sachs Initiates Coverage on Stoke Therapeutics With Buy Rating, $44 Price Target - marketscreener.com
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer - Business Wire
STOK Initiates Coverage On Goldman Sachs -- Price Target Announced at $44 - GuruFocus
Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential By Investing.com - Investing.com South Africa
Candriam S.C.A. Has $16.35 Million Stake in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Insiders Sold US$1.3m Of Shares Suggesting Hesitancy - Moomoo
Stoke Therapeutics, Inc. Actuals & Estimates (DUS:0GT) - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Urogen Pharma (URGN), Stoke Therapeutics (STOK) - The Globe and Mail
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Stoke Therapeutics Announces Updates to Timelines for the Complet - The National Law Review
Needham Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Stoke Therapeutics highlights antisense pipeline as genetic medicine interest grows - AD HOC NEWS
Stoke Therapeutics holds the focus. Investors await the next evidence - Ad-hoc-news.de
1.84%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):